Inflammation: Extinguishing the fires within

Clinical Pharmacology and Therapeutics

Volumn 87, Issue 4, 2010, Pages 375-379

  Vassileva, V ^a   Piquette Miller, M ^b  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOHYDRATE; CELECOXIB; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INFLIXIMAB; NONSTEROID ANTIINFLAMMATORY AGENT; PROTEIN; SALICYLIC ACID DERIVATIVE; SALSALATE; TOCILIZUMAB;

ADAPTIVE IMMUNITY; ALLERGY; ALZHEIMER DISEASE; ARTHRITIS; ATHEROSCLEROSIS; CARBOHYDRATE METABOLISM; CARDIOVASCULAR DISEASE; CHRONIC DISEASE; CLINICAL TRIAL; DIABETES MELLITUS; DISEASE COURSE; EDITORIAL; GENE EXPRESSION; GENE MUTATION; HEAT; HISTORY; HUMAN; HYPERTRIGLYCERIDEMIA; INFECTION; INFLAMMATION; INNATE IMMUNITY; INTROSPECTION; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PAIN; PHYSICIAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIDE EFFECT; SWELLING; TREATMENT RESPONSE; WEIGHT GAIN;

ANIMALS; BIOLOGICAL MARKERS; CHRONIC DISEASE; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; INFLAMMATION; PHARMACEUTICAL PREPARATIONS; TREATMENT OUTCOME;

EID: 77949811357     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2010.10     Document Type: Editorial

References (14)

1. Rocha, E. & Silva, M. A brief survey of the history of inflammation. 1978. Agents Actions 43, 86-90 (1994).
2. Shoelson, S.E., Lee, J. & Goldfine, A.B. Inflammation and insulin resistance. J. Clin. Invest. 116, 1793-1801 (2006).
3. Mathieu, P., Lemieux, I. & Despres, J.-P. Obesity, inflammation, and cardiovascular risk. Clin. Pharmacol. Ther. 87, 407-416 (2010).
4. Libby, P. How our growing understanding of inflammation has reshaped the way we think of disease and drug development. Clin. Pharmacol. Ther. 87, 389-391 (2010).
5. Balkwill, F. & Mantovani, A. Cancer and inflammation: implications for pharmacology and therapeutics. Clin. Pharmacol. Ther. 87, 401-406 (2010).
6. Febbraio, M.A., Rose-John, S. & Pedersen, B.K. Is interleukin-6 receptor blockade the holy grail for inflammatory diseases? Clin. Pharmacol. Ther. 87, 396-398 (2010).
7. O'Connor, M.-F. & Irwin M.R. Links between behavioral factors and inflammation. Clin. Pharmacol. Ther. 87, 479-482 (2010).
8. Morgan, E.T. Impact of infectious and inflammatory disease on cytochrome P450-mediated drug metabolism and pharmacokinetics. Clin. Pharmacol. Ther. 85, 434-438 (2009).
9. Schmith V.D. & Foss, J.F. Inflammation: planning for a source of pharmacokinetic/pharmacodynamic variability in translational studies. Clin. Pharmacol. Ther. 87, 488-491 (2010).
10. Petrovic, V., Teng, S. & Piquette-Miller, M. Regulation of drug transporters during infection and inflammation. Mol. Interv. 7, 99-111 (2007).
11. Robertson, G.R., Liddle, C. & Clarke, S.J. Inflammation and altered drug clearance in cancer; transcriptional repression of a human CYP3A4 transgene in tumor-bearing mice. Clin. Pharmacol. Ther. 83, 894-897 (2008).
12. Dreisbach, A.W. The influence of chronic renal failure on drug metabolism and transport. Clin. Pharmacol. Ther. 86, 553-556 (2009).
13. Huang, S-M. et al. Therapeutic protein-drug interactions and implications for drug development. Clin. Pharmacol. Ther. 87, 497-503 (2010).
14. Rocha, V.Z. & Libby, P. Obesity, inflammation, and atherosclerosis. Nat. Rev. Cardiol. 6, 399-409 (2009).